This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalized therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of "all-comer" treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalized treatment allocation has the substantial potential to reduce pancreatic cancer mortality.

Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine

Casolino, R;Malleo, G;Paiella, S;Bassi, C;Milella, M;
2021-01-01

Abstract

This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalized therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of "all-comer" treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly important in the preoperative, potentially curable setting, where a personalized treatment allocation has the substantial potential to reduce pancreatic cancer mortality.
2021
Pancreatic cancer
neoadjuvant
precision medicine
predictive biomarkers
preoperative
prognostic biomarkers
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1030879
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 40
social impact